Trinity Biotech
TRIB
19 hedge funds and large institutions have $5.93M invested in Trinity Biotech in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.03% → 0.03% (-0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1% less capital invested
Capital invested by funds: $5.96M → $5.93M (-$33.4K)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
76% less call options, than puts
Call options by funds: $4K | Put options by funds: $17K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$108K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15K |
| 3 |
DAS
Dynamic Advisor Solutions
Phoenix,
Arizona
|
+$9.72K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$1.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonehill Capital Management
New York
|
-$72.6K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$56.5K |
| 3 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
-$49.5K |
| 4 |
AWS
Atria Wealth Solutions
New York
|
-$32.2K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14.1K |
TRIB Hedge Fund Activity: Q2 2023 in Review
19 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2023, worth a combined $5.93M — down 0.56% from $5.96M a quarter earlier.
Fund positioning in TRIB was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $108K. The largest seller was Stonehill Capital Management, cutting an estimated $72.6K.
- 19 institutional investors held Trinity Biotech (TRIB) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $5.93M of Trinity Biotech stock for Q2 2023, down 0.56% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q2 2023 and 4 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q2 2023 was Cambridge Investment Research Advisors, an estimated $108K added.
- The largest Trinity Biotech seller in Q2 2023 was Stonehill Capital Management, an estimated $72.6K sold.
Based on aggregated 13F filings for Q2 2023.